AU2014257650A1 - Anti-cancer treatments with anti-EGFR antibodies having a low fucosylation - Google Patents

Anti-cancer treatments with anti-EGFR antibodies having a low fucosylation Download PDF

Info

Publication number
AU2014257650A1
AU2014257650A1 AU2014257650A AU2014257650A AU2014257650A1 AU 2014257650 A1 AU2014257650 A1 AU 2014257650A1 AU 2014257650 A AU2014257650 A AU 2014257650A AU 2014257650 A AU2014257650 A AU 2014257650A AU 2014257650 A1 AU2014257650 A1 AU 2014257650A1
Authority
AU
Australia
Prior art keywords
egfr
egfr antibody
antibody according
reduced fucose
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2014257650A
Other languages
English (en)
Inventor
Antje Danielczyk
Steffen Goletz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glycotope GmbH
Original Assignee
Glycotope GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycotope GmbH filed Critical Glycotope GmbH
Publication of AU2014257650A1 publication Critical patent/AU2014257650A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2014257650A 2013-04-22 2014-04-22 Anti-cancer treatments with anti-EGFR antibodies having a low fucosylation Abandoned AU2014257650A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP13002106.6 2013-04-22
EP13002106 2013-04-22
EP13002108 2013-04-22
EP13002108.2 2013-04-22
PCT/EP2014/058118 WO2014173886A1 (en) 2013-04-22 2014-04-22 Anti-cancer treatments with anti-egfr antibodies having a low fucosylation

Publications (1)

Publication Number Publication Date
AU2014257650A1 true AU2014257650A1 (en) 2015-11-12

Family

ID=50729450

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014257650A Abandoned AU2014257650A1 (en) 2013-04-22 2014-04-22 Anti-cancer treatments with anti-EGFR antibodies having a low fucosylation

Country Status (13)

Country Link
US (1) US20160068609A1 (enExample)
EP (1) EP2989126A1 (enExample)
JP (1) JP2016516800A (enExample)
KR (1) KR20150144804A (enExample)
CN (1) CN105229030A (enExample)
AU (1) AU2014257650A1 (enExample)
BR (1) BR112015025955A2 (enExample)
CA (1) CA2908819A1 (enExample)
EA (1) EA201591977A1 (enExample)
MX (1) MX2015014773A (enExample)
SG (1) SG11201507743XA (enExample)
WO (1) WO2014173886A1 (enExample)
ZA (1) ZA201507246B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
CN105820248A (zh) * 2015-01-07 2016-08-03 上海张江生物技术有限公司 一种新型抗egfr单克隆抗体的制备方法及应用
CN105399830B (zh) * 2015-09-08 2019-11-19 北京天广实生物技术股份有限公司 抗egfr人源化单克隆抗体、其制备方法及用途
WO2017120613A1 (en) * 2016-01-10 2017-07-13 Sorrento Therapeutics, Inc. Improved safety for treating cancers with a glycosylated chimeric antibody to egfr
HUE058745T2 (hu) * 2016-04-27 2022-09-28 Green Cross Corp Hatóanyagként epidermális növekedési faktor receptorhoz specifikusan kötõdõ antitestet tartalmazó gyógyászati készítmény rák áttételének gátlására
WO2017205465A2 (en) * 2016-05-24 2017-11-30 Griswold Karl Edwin Antibodies and methods of making same
WO2018013673A1 (en) 2016-07-13 2018-01-18 Reform Biologics, Llc Stabilizing excipients for therapeutic protein formulations
KR101884614B1 (ko) 2016-10-11 2018-08-02 신일제약주식회사 Fab 단편 및 이의 용도
CN111315776A (zh) * 2017-03-29 2020-06-19 葛莱高托普有限公司 Pd-l1和ta-muc1抗体
CN118267470A (zh) * 2017-04-13 2024-07-02 赛罗帕私人有限公司 抗SIRPα抗体
KR20250005551A (ko) * 2017-05-29 2025-01-09 엑셀리시스, 인코포레이티드 암 연관 면역억제의 억제제
US20210269530A1 (en) * 2018-05-14 2021-09-02 Harpoon Therapeutics, Inc. Conditionally activated binding protein comprising a sterically occluded target binding domain
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
US20220008419A1 (en) * 2018-11-14 2022-01-13 Kanazawa Medical University Pharmaceutical composition for treating diffuse-type gastric cancer
CN112300278A (zh) * 2019-07-25 2021-02-02 上海交通大学 抗人egfr嵌合抗体及其制备方法和用途
EP4139357A1 (en) * 2020-04-24 2023-03-01 Merus N.V. Treatment of cancers with an antibody that binds lgr5 and egfr
CN115960214A (zh) * 2021-10-12 2023-04-14 中国科学院分子细胞科学卓越创新中心 中和呼吸道合胞病毒的全人抗体的设计及应用
WO2023154796A2 (en) * 2022-02-09 2023-08-17 Dragonfly Therapeutics, Inc. Pharmaceutical formulations and therapeutic uses of multi-specific binding proteins that bind egfr, nkg2d, and cd16

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
WO2000061739A1 (fr) 1999-04-09 2000-10-19 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
ATE309385T1 (de) 2000-06-28 2005-11-15 Glycofi Inc Verfahren für die herstellung modifizierter glykoproteine
NZ532526A (en) 2001-10-25 2007-01-26 Genentech Inc Compositions comprising a glycoprotein having a Fc region
WO2003084569A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Drug containing antibody composition
FR2858235B1 (fr) 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
WO2006082515A2 (en) * 2005-02-07 2006-08-10 Glycart Biotechnology Ag Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
ES2620261T3 (es) 2006-09-10 2017-06-28 Glycotope Gmbh Uso de células humanas de origen leucémico mieloide para expresión de anticuerpos
US20110200595A1 (en) * 2010-02-18 2011-08-18 Roche Glycart TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
WO2012020059A1 (en) * 2010-08-10 2012-02-16 Glycotope Gmbh Humanized egfr antibodies
DK2603528T3 (en) * 2010-08-10 2016-11-28 Glycotope Gmbh FAB-glycosylated ANTIBODIES

Also Published As

Publication number Publication date
CN105229030A (zh) 2016-01-06
EA201591977A1 (ru) 2016-06-30
WO2014173886A1 (en) 2014-10-30
BR112015025955A2 (pt) 2017-10-17
CA2908819A1 (en) 2014-10-30
JP2016516800A (ja) 2016-06-09
ZA201507246B (en) 2016-12-21
KR20150144804A (ko) 2015-12-28
US20160068609A1 (en) 2016-03-10
MX2015014773A (es) 2016-03-04
SG11201507743XA (en) 2015-11-27
EP2989126A1 (en) 2016-03-02

Similar Documents

Publication Publication Date Title
US20160068609A1 (en) Anti-cancer treatments with anti-egfr antibodies having a low fucosylation
TWI791422B (zh) 用於癌症治療之單獨fgfr2抑制劑或與免疫刺激劑組合
KR102749931B1 (ko) 암 치료에서 화학요법제와 병용되는 항-fgfr2 항체
EP3733704A1 (en) Anti-pd-l1 antibody and uses thereof
WO2018014864A1 (en) Bispecific anti-her2 antibody
KR20180083895A (ko) Cd47 및 egfr의 이중 표적화를 이용한 암의 치료
US10377833B2 (en) Bispecific anti-HER2 antibody
AU2016206155B2 (en) A novel anti-EGFR monoclonal antibody, method of making, and use thereof
JP2024038034A (ja) 膀胱癌の抗ｐｄ－ｌ１抗体治療
AU2013291964B2 (en) Novel therapeutic treatments with anti-HER2 antibodies having a low fucosylation
TW201925230A (zh) 以抗egfr療法治療癌症的組成物及方法
CN110177807B (zh) 使用抗MUC1抗体和ErbB抑制剂的抗癌治疗
JP2025537137A (ja) 抗ｃｃｒ８抗体、化学療法及び免疫療法の組み合わせを使用する抗がん療法
JP2024537091A (ja) 少なくともｅｇｆｒに結合する抗体を使用した、免疫チェックポイント阻害剤で治療された高いｅｇｆｒ発現を有するがんの治療
US20250215087A1 (en) Combination therapy of kras inhibitor and treg depleting agent

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period